Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth Submits More Viviant Data To FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm acknowledges recent submission could push back December user fee date for NDA for prevention of osteoporosis.

You may also be interested in...



Wyeth’s Viviant Receives Second “Approvable” Letter For Osteoporosis Prevention

FDA requests additional data on stroke and thrombotic events in the letter, Wyeth reports.

Wyeth’s Viviant Receives Second “Approvable” Letter For Osteoporosis Prevention

FDA requests additional data on stroke and thrombotic events in the letter, Wyeth reports.

Wyeth’s Viviant “Approvable” For Prevention Of Postmenopausal Osteoporosis

Firm continues to plan an additional submission this year for an osteoporosis treatment claim.

Topics

UsernamePublicRestriction

Register

PS065529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel